Area of research
Surgery · Oncology
Research interest
Research interests include Bladder and Urothelial Cancer Treatments, Cancer Immunotherapy and Biomarkers, Fibroblast Growth Factor Research, and Cancer Genomics and Diagnostics.
Molecular heterogeneity in urothelial carcinoma and determinants of clinical benefit to PD-L1 blockade
ctDNA guiding adjuvant immunotherapy in urothelial carcinoma
Adjuvant atezolizumab versus observation in muscle-invasive urothelial carcinoma (IMvigor010): a multicentre, open-label, randomised, phase 3 trial
Association of baseline systemic corticosteroid use with overall survival and time to next treatment in patients receiving immune checkpoint inhibitor therapy in real-world US oncology practice for advanced non-small cell lung cancer, melanoma, or urothelial carcinoma
IMvigor010: Primary analysis from a phase III randomized study of adjuvant atezolizumab (atezo) versus observation (obs) in high-risk muscle-invasive urothelial carcinoma (MIUC).
“Real-world” outcomes and prognostic indicators among patients with high-risk muscle-invasive urothelial carcinoma